{"title":"UEG 2024 周","authors":"Rob Brierley","doi":"10.1016/s2468-1253(24)00354-6","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Cendakimab for eosinophilic oesophagitis</h2>Cendakimab, a monoclonal antibody that inhibits IL-13 binding to both IL-13Rα1 and IL-13Rα2, improved 24-week outcomes in patients with eosinophilic oesophagitis, according to data presented by Alain M Schoepfer (Lausanne, Switzerland). In a phase 3 trial, adults and adolescents with active eosinophilic oesophagitis were randomly assigned to receive subcutaneous cendakimab at 360 mg every week for 48 weeks (n=143), cendakimab 360 mg every week for 24 weeks followed by the same dose every other</section></section><section><section><h2>TUSCANY-2</h2>RO7790121, an anti-TL1A monoclonal antibody, could improve outcomes for patients with moderately to severely active ulcerative colitis who have failed previous treatment, according to results from the phase 2B TUSCANY-2 trial, presented by Silvio Danese (Milan, Italy). In this dose-ranging trial, patients were randomly assigned to receive RO7790121 subcutaneously once a month at 50 mg, 150 mg, or 450 mg, or placebo once a month for a 12-week induction period; in the 40-week treat-through</section></section><section><section><h2>SHINE-1</h2>In the phase 2 SHINE-1 trial, paediatric patients (2 to <18 years) with moderate-to-severe ulcerative colitis who had an inadequate response, loss of response, or intolerance to previous treatment, or who had corticosteroid-dependent colitis, were treated with mirikizumab at a dose determined by bodyweight. Patients with a clinical response per modified Mayo score at week 12 entered a maintenance period, receiving subcutaneous mirikizumab every 4 weeks (with dose again determined by patient</section></section><section><section><h2>Partially hydrolysed guar gum for chronic constipation</h2>Partially hydrolysed guar gum, a water-soluble fibre derived from guar seed, resulted in greater improvements in frequency of spontaneous bowel movements than did placebo after 6 weeks among patients with functional constipation or IBS-constipation. In a double-blind randomised trial presented by Sílvia Delgado-Aros (Vervey, Switzerland), participants were randomly assigned to receive partially hydrolysed guar gum (10 g/day) or placebo (80 patients in each group). At 6 weeks, patients in the</section></section>","PeriodicalId":30,"journal":{"name":"Biomacromolecules","volume":null,"pages":null},"PeriodicalIF":5.5000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"UEG Week 2024\",\"authors\":\"Rob Brierley\",\"doi\":\"10.1016/s2468-1253(24)00354-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h2>Section snippets</h2><section><section><h2>Cendakimab for eosinophilic oesophagitis</h2>Cendakimab, a monoclonal antibody that inhibits IL-13 binding to both IL-13Rα1 and IL-13Rα2, improved 24-week outcomes in patients with eosinophilic oesophagitis, according to data presented by Alain M Schoepfer (Lausanne, Switzerland). In a phase 3 trial, adults and adolescents with active eosinophilic oesophagitis were randomly assigned to receive subcutaneous cendakimab at 360 mg every week for 48 weeks (n=143), cendakimab 360 mg every week for 24 weeks followed by the same dose every other</section></section><section><section><h2>TUSCANY-2</h2>RO7790121, an anti-TL1A monoclonal antibody, could improve outcomes for patients with moderately to severely active ulcerative colitis who have failed previous treatment, according to results from the phase 2B TUSCANY-2 trial, presented by Silvio Danese (Milan, Italy). In this dose-ranging trial, patients were randomly assigned to receive RO7790121 subcutaneously once a month at 50 mg, 150 mg, or 450 mg, or placebo once a month for a 12-week induction period; in the 40-week treat-through</section></section><section><section><h2>SHINE-1</h2>In the phase 2 SHINE-1 trial, paediatric patients (2 to <18 years) with moderate-to-severe ulcerative colitis who had an inadequate response, loss of response, or intolerance to previous treatment, or who had corticosteroid-dependent colitis, were treated with mirikizumab at a dose determined by bodyweight. Patients with a clinical response per modified Mayo score at week 12 entered a maintenance period, receiving subcutaneous mirikizumab every 4 weeks (with dose again determined by patient</section></section><section><section><h2>Partially hydrolysed guar gum for chronic constipation</h2>Partially hydrolysed guar gum, a water-soluble fibre derived from guar seed, resulted in greater improvements in frequency of spontaneous bowel movements than did placebo after 6 weeks among patients with functional constipation or IBS-constipation. In a double-blind randomised trial presented by Sílvia Delgado-Aros (Vervey, Switzerland), participants were randomly assigned to receive partially hydrolysed guar gum (10 g/day) or placebo (80 patients in each group). At 6 weeks, patients in the</section></section>\",\"PeriodicalId\":30,\"journal\":{\"name\":\"Biomacromolecules\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.5000,\"publicationDate\":\"2024-10-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomacromolecules\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/s2468-1253(24)00354-6\",\"RegionNum\":2,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomacromolecules","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2468-1253(24)00354-6","RegionNum":2,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Cendakimab, a monoclonal antibody that inhibits IL-13 binding to both IL-13Rα1 and IL-13Rα2, improved 24-week outcomes in patients with eosinophilic oesophagitis, according to data presented by Alain M Schoepfer (Lausanne, Switzerland). In a phase 3 trial, adults and adolescents with active eosinophilic oesophagitis were randomly assigned to receive subcutaneous cendakimab at 360 mg every week for 48 weeks (n=143), cendakimab 360 mg every week for 24 weeks followed by the same dose every other
TUSCANY-2
RO7790121, an anti-TL1A monoclonal antibody, could improve outcomes for patients with moderately to severely active ulcerative colitis who have failed previous treatment, according to results from the phase 2B TUSCANY-2 trial, presented by Silvio Danese (Milan, Italy). In this dose-ranging trial, patients were randomly assigned to receive RO7790121 subcutaneously once a month at 50 mg, 150 mg, or 450 mg, or placebo once a month for a 12-week induction period; in the 40-week treat-through
SHINE-1
In the phase 2 SHINE-1 trial, paediatric patients (2 to <18 years) with moderate-to-severe ulcerative colitis who had an inadequate response, loss of response, or intolerance to previous treatment, or who had corticosteroid-dependent colitis, were treated with mirikizumab at a dose determined by bodyweight. Patients with a clinical response per modified Mayo score at week 12 entered a maintenance period, receiving subcutaneous mirikizumab every 4 weeks (with dose again determined by patient
Partially hydrolysed guar gum for chronic constipation
Partially hydrolysed guar gum, a water-soluble fibre derived from guar seed, resulted in greater improvements in frequency of spontaneous bowel movements than did placebo after 6 weeks among patients with functional constipation or IBS-constipation. In a double-blind randomised trial presented by Sílvia Delgado-Aros (Vervey, Switzerland), participants were randomly assigned to receive partially hydrolysed guar gum (10 g/day) or placebo (80 patients in each group). At 6 weeks, patients in the
期刊介绍：
Biomacromolecules is a leading forum for the dissemination of cutting-edge research at the interface of polymer science and biology. Submissions to Biomacromolecules should contain strong elements of innovation in terms of macromolecular design, synthesis and characterization, or in the application of polymer materials to biology and medicine.
Topics covered by Biomacromolecules include, but are not exclusively limited to: sustainable polymers, polymers based on natural and renewable resources, degradable polymers, polymer conjugates, polymeric drugs, polymers in biocatalysis, biomacromolecular assembly, biomimetic polymers, polymer-biomineral hybrids, biomimetic-polymer processing, polymer recycling, bioactive polymer surfaces, original polymer design for biomedical applications such as immunotherapy, drug delivery, gene delivery, antimicrobial applications, diagnostic imaging and biosensing, polymers in tissue engineering and regenerative medicine, polymeric scaffolds and hydrogels for cell culture and delivery.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
